Chronic renal ischemia: Implications for cardiovascular disease risk

Journal of Vascular and Interventional Radiology

Volumn 13, Issue 12, 2002, Pages 1187-1198

  Murphy, Timothy P ^a   Rundback, John H ^b   Cooper, Christopher ^c   Kiernan, M Susan ^a  

^a BROWN UNIVERSITY   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Hypertension, renovascular; Kidney, blood supply; Renal arteries, stenosis or obstruction

Indexed keywords

ANGIOTENSIN; CATECHOLAMINE; ENDOTHELIN; RENIN;

ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; ENDOTHELIUM CELL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY ISCHEMIA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK FACTOR;

EID: 0036899120     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(07)61964-2     Document Type: Review

References (139)

1. Losito A, Fagugli RM, Zampi I, et al. Comparison of target organ damage in renovascular and essential hypertension. Am J Hypertens 1996; 9:1062-1067.
2. Frolich ED, Ulrych M, Tarazi RC, et al. A hemodynamic comparison of essential and renovascular hypertension: Cardiac output and total peripheral resistance: Supine and tilted patients. Circulation 1967; 35:289-297.
3. Simon N, Franklin S, Bleifer KH, Maxwell MM. Clinical characteristics of renovascular hypertension. JAMA 1972; 220:1209-1218.
4. Davis BA, Crook HE, Vestar RE, Oates JA. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive nephropathy. N Engl J Med 1979; 301:1273-1276.
5. Ram CVS. Renovascular hypertension. Curr Opin Nephrol Hypertens 1997; 6:575-579.
6. Vokonas PS, Kannel WB, Cupples LA. Epidemiology and risk of hypertension in the elderly: The Framingham Study. J Hypertens 1988; 6(suppl 1):S3-S9.
7. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996; 275:1571-1576.
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
9. Armery A, Brixxo P, Clement D, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1(8442):1349-1354.
10. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293:1145-1152.
11. Dahlof B, Lindeholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1284.
12. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ 1992; 304:405-412.
13. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: An overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15:967-978.
14. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: Studies in a random population sample. BMJ 1976; 2(6035):554-556.
15. Ferguson RK. Cost and yield of the hypertensive evaluation: Experience of a community-based referral clinic. Ann Intern Med 1975; 82:761-765.
16. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147:1289-1293.
17. Derkx FH, Schalekamp MA. Renal artery stenosis and hypertension. Lancet 1994; 344:237-239.
18. Kaplan NM. Clinical Hypertension. Baltimore: Williams & Wilkins, 1990; 303-324.
19. Maxwell MH, Bleifer KH, Franklin SS, Varady PD. Cooperative study of renovascular hypertension: Demographic analysis of the study. JAMA 1972; 220:1195-1204.
20. Rundback JH, Murphy TP, Cooper C, Weintraub J. Chronic renal ischemia: Pathophysiologic mechanisms of cardiovascular and renal disease. J Vasc Interv Radiol 2002;13:1085-1092.
21. Liard JF, Cowley AW Jr, McCaa RE, McCaa CS, Guyton AC. Renin, aldosterone, body fluid volumes, and the baroreceptor reflex in the development and reversal of Goldblatt hypertension in conscious dogs. Circ Res 1974; 34:549-560.
22. Ayers CR, Katholi RE, Vaughan ED Jr, et al. Intrarenal renin-angiotensinsodium interdependent mechanism controlling postclamp renal artery pressure and renin release in the conscious dog with chronic one-kidney Goldblatt hypertension. Circ Res 1977; 40:238-242.
23. Mulrow PJ, Franco-Saenz R. The adrenal renin-angiotensin system: A local hormonal regulator of aldosterone production. J Hypertens 1996; 14:173-176.
24. van Velzer DA, Burge CH, Morris GC. Arteriosclerotic narrowing of renal arteries associated with hypertension. AJR Am J Roentgenol 1961; 85:807-818.
25. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2069.
26. Goldblatt H LJ, Hanzal RF, Summerville WW. Studies on experimental hypertension. I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934; 59:347-380.
27. Anderson WP, Korner P, Angus JA, Johnston CI. Contribution of stenosis resistance to the rise in total peripheral resistance during experimental renal hypertension in conscious dogs. Clin Sci 1981; 61:663-670.
28. Schoenberg SO, Bock M, Kallinowski F, Just A. Correlation of hemodynamic impact and morphologic degree of renal artery stenosis in a canine model. J Am Soc Nephrol 2000; 11:2190-2198.
29. Korner PI. The sixth Volhard Lecture: Causal and homeostatic factors in hypertension. Clin Sci (Lond) 1982; 63(suppl 8):5S-26S.
30. Woods RL, Anderson WP, Korner PI. Renal and systemic effects of enalapril in chronic one-kidney hypertension. Hypertension 1986; 8:109-116.
31. Selig S, Anderson W, Korner P, Casley D. The role of angiotensin II in the development of hypertension and in the maintenance of glomerular filtration rate during 48 hours of renal artery stenosis in conscious dogs. J Hypertens 1983; 1:351-355.
32. Korner PI. Cardiovascular hypertrophy and hypertension: Causes and consequences. Blood Press 1995; 4(suppl 2):6-16.
33. Vensel LA, Devereux RB, Pickering TG, Herrold EM, Borer JS, Laragh JH. Cardiac structure and function in renovascular hypertension produced by unilateral and bilateral renal artery stenosis. Am J Cardiol 1986; 58:575-582.
34. Teunissen KE, Postma CT, van Jaarsveld BC, Derkx FH, Thien T. Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty. J Hypertens 1997; 15(part 2):1791-1796.
35. Schreij G, van Es PN, Schiffers PM, Lavrijssen AT, de Leeuw PW. 'Captopril test,' with blood pressure and peripheral renin as response variables in hypertensive patients with suspected renal artery stenosis. J Hum Hypertens 1995; 9:741-746.
36. Martin LG, Cork RD, Wells JO. Renal vein renin analysis: Limitations of its use in predicting benefit from percutaneous angioplasty. Cardiovasc Intervent Radiol 1993; 16:76-80.
37. Johansson M, Herlitz H, Jensen G, Rundqvist B, Friberg P. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. J Hypertens 1999; 17:1743-1750.
38. Miyajima E, Yamada Y, Yoshida Y, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17:1057-1062.
39. Mathias CJ, Kooner JS, Peart S. Neurogenic components of hypertension in human renal artery stenosis. Clin Exp Hypertens 1987; 9(suppl 1):293-306.
40. Higashi Y, Sasaki, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346:1954-1962.
41. Volpe M, Camargo MJF, Mueller FB, et al. Relation of plasma renin to end1187-1198 organ damage and to protection of K+ feeding in stroke-prone hypertensive rats. Hypertension 1990; 15:318-326.
42. Meyrier A. Vascular mechanisms of renal fibrosis: Vasculonephropathies and arterial hypertension. Bull Acad Natl Med 1999; 183:33-45; discussion, 45-46.
43. Losito A, Zampi I, Fortunati F, Del Favero A. Abnormal proteinuric response to amino acid infusion in essential hypertension. J Nephrol 1993; 5:85-88.
44. Holley KE, Hunt JC, Brown AL, Kincaid OW, Sheps SG. Renal artery stenosis: A clinical-pathologic study in normotensive and hypertensive patients. Am J Med 1964; 37:14-22.
45. Roberts JC, Moses C, Wilkins RH. Autopsy studies in atherosclerosis. I. Distribution and severity of atherosclerosis in patients dying without morphologic evidence of atherosclerotic catastrophe. Circulation 1959; 20:511-519.
46. Roberts JC, Wilkins RH, Moses C. Autopsy studies in atherosclerosis. II. Distribution and severity of atherosclerosis in patients dying with morphologic evidence of atherosclerotic catastrophe. Circulation 1959; 20:520-526.
47. Rossi GP, Rossi A, Zanin L, et al. Excess prevalence of extracranial carotid artery lesions in renovascular hypertension. Am J Hypertens 1992; 5:8-15.
48. Horvath JS, Waugh RC, Tiller DJ, Duggin GG. The detection of renovascular hypertension: A study of 490 patients by renal angiography. Q J Med 1982; 51(202):139-146.
49. Miralles M, Corominas A, Cotillas J, Castro F, Clara A, Vidal-Barraquer F. Screening for carotid and renal artery stenoses in patients with aortoiliac disease. Ann Vasc Surg 1998; 12:17-22.
50. Olin JW, Melia M, Young JR, Graor RA, Risius B. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 1990; 88(1N):46N-51N.
51. Valentine RJ, Clagett P, Miller GL, Myers SI, Martin JD, Chervu A. The coronary risk of unsuspected renal artery stenosis. J Vasc Surg 1993; 18:433-440.
52. Iglesias JI, Hamburger RJ, Feldman L, Kaufman JS. The natural history of incidental renal artery stenosis in patients with aortoiliac vascular disease. Am J Med 2000; 109:642-647.
53. Wachtell K, Ibsen H, Olsen MH, et al. Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension. J Hum Hypertens 1996; 10:83-85.
54. Missouris CG, Belli AM, MacGregor. "Apparent" heart failure: A syndrome caused by renal artery stenoses. Heart 2000; 83:152-155.
55. Swartbol P, Thorvinger BO, Parsson H, Norgren L. Renal artery stenosis in patients with peripheral vascular disease and its correlation to hypertension: A retrospective study. Int Angiol 1992; 11:195-199.
56. Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J 1998; 136:913-918.
57. Song HY, Hwang JH, Noh H, et al. The prevalence and associated risk factors of renal artery stenosis in patients undergoing cardiac catheterization. Yonsei Med J 2000; 41:219-225.
58. Harding MB, Smith LR, Himmelstein SI, et al. Renal artery stenosis: Prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 1992; 2:1608-1616.
59. Jean WJ, al-Bitar I, Zwicke DL, Port SC, Schmidt DH, Bajwa TK. High incidence of renal artery stenosis in patients with coronary artery disease. Cathet Cardiovasc Diagn 1994; 32:8-10.
60. Uzu T, Inoue T, Fujii T, Nakamura S, Inenaga T, Yutani C, Kimura G. Prevalence and predictors of renal artery stenosis in patients with myocardial infarction. Am J Kidney Dis 1997; 29:733-738.
61. Conlon PJ, Little MA, Pieper K, Mark DB. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidnev Int 2001; 60:1490-1497.
62. Swartbol P, Parsson H, Thorvinger B, Norgren L. To what extent does peripheral vascular disease and hypertension predict renal artery stenosis? Int Angiol 1994; 13:109-114.
63. MacDowall P, Kalra PA, O'Donoghue DJ, Waldek S, Mamtora H, Brown K. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet 1998; 352:13-16.
64. Dean RH. Surgical management of renovascular disorders. In: Rutherford RB, ed. Vascular Surgery, 3rd Edition. Philadelphia: WB Saunders 1989;1211-1217.
65. Gross CM, Kramer J, Weingartner O, et al. Determination of renal arterial stenosis severity: Comparison of pressure gradient and vessel diameter. Radiology 2001; 220:751-756.
66. Nahman NS Jr, Maniam P, Hernandez RA Jr, et al. Renal artery pressure gradients in patients with angiographic evidence of atherosclerotic renal artery stenosis. Am J Kidney Dis 1994; 24:695-699.
67. Lewis BE, Leya FS, Johnson SA, et al. Improved hemodynamic, angiographic and functional results after renal artery stenting. J Invas Cardiol 1994; 6:136-140.
68. Messerli FH, Genest J, Nowaczynski W, et al. Hypertension with renal arterial stenosis: Humoral, hemodynamic and histopathologic factors. Am J Cardiol 1975; 36:702-707.
69. Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Friberg P. Increased sympathetic nerve activity in renovascular hypertension. Circulation 1999; 99:2537-2542.
70. Dorros G, Jaff M, Mathiak L, et al. Four-year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis. Circulation 1998; 98:642-647.
71. Rocha-Singh KJ, Mishkel GJ, Katholi RE, et al. Clinical predictors of improved long-term blood pressure control after successful stenting of hypertensive patients with obstructive renal artery atherosclerosis. Cathet Cardiovasc Interv 1999; 47:167-172.
72. de Simone G, Devereux RB, Volpe M, Camargo MJ, Wallerson DC, Laragh JH. Relation of left ventricular hypertrophy, afterload, and contractility to left ventricular performance in Goldblatt hypertension. Am J Hypertens 1992; 5(part 1):292-301.
73. Broughton A, Korner PI. Left ventricular pump function in renal hypertensive dogs with cardiac hypertrophy. Am J Physiol 1986; 251(part 2):H1260-H1266.
74. Suzuki T, Abe H, Nagata S, et al. Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism. Am J Cardiol 1988; 62:1224-1227.
75. Meissner MD, Wilson AR, Jessup M. Renal artery stenosis in heart failure. Am J Cardiol 1988; 62:1307-1308.
76. Khosla S, White CJ, Collins TJ, Jenkins S, Shaw D, Ramee SR. Effects of renal artery stent implantation inpatients with renovascular hypertension presenting with unstable angina or congestive heart failure. Am J Cardiol 1997; 80:363-366.
77. MacMahon S, Collins G, Rautahatju P, et al. Electrocardiographic left ventricular hypertrophy and effects of anti-hypertensive drug therapy in the participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1989; 63:202-210.
78. Sorensen MB, Bille Brahe NE. Preoperative haemodynamic evaluation of patients submitted for renal artery stenosis. Acta Anaesthesiol Scand 1984; 28:334-338.
79. Gavras H, Brown JJ, Lever AF, MacAdam RF, Robertson JI. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 1971; 2(7714):19-22.
80. Yamazaki T, Shiojima I, Komuro I, et al. Involvement of the renin angiotensin system in the development of left ventricular hypertrophy and dysfunction. J Hypertens 1994; 12(suppl 9):S23-S27.
81. Hocher B, George I, Rebstock J, et al. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 1999; 33:816-822.
82. Wahlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulinlike growth factor I increases in early renal hypertension. Hypertension 1992; 19:25-32.
83. Iwanaga Y, Kihara Y, Inagaki K, et al. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation 2001; 104:606-612.
84. Robertson AL Jr, Khairalla PA. Angiotensin II: Rapid localization in nuclei of smooth and cardiac muscle. Science 1971; 172:1138-1139.
85. Phillips PA. Interaction between endothelin and angiotensin II. Clin Exp Pharmacol Physiol 1999; 26:517-518.
86. Ehmke H, Faulhaber J, Munter K, Kirchengast M, Wiesner RJ. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension 1999; 33:954-960.
87. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
88. Kannel WB, Cobb J. Left ventricular hypertrophy and mortality - Results from the Framingham Study. Cardiology 1992; 81:291-298.
89. Kannel WB. Left ventricular hypertrophy as a risk factor: The Framingham experience. J Hypertens 1991; 9(suppl):S3-S8.
90. Devereux RB, Okin PM, Roman MJ. Left ventricular hypertrophy as a surrogate end-point in hypertension. Clin Exp Hypertens 1999; 21:583-593.
91. Sullivan JM, Vander Zwaag RV, elZeky F, Ramanathan KB, Mirvis DM. Left ventricular hypertrophy: Effect on survival. J Am Coll Cardiol 1993; 22:508-513.
92. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140:848-856.
93. Symonides B, Chodakowska J, Januszewicz A, et al. Effects of the correction of renal artery stenosis on blood pressure, renal function and left ventricular morphology. Blood Press 1999; 8:141-150.
94. Jacobsen HR. Ischemic renal disease: An overlooked clinical entity? Kidney Int 1988; 34:729-743.
95. Hunt JC, Sheps SG, Harrison EG, Strong CG, Bernatz PE. Renal and renovascular hypertension: A reasoned approach to diagnosis and management. Arch Intern Med 1974; 133:988-999.
96. Mailloux LU, Napolitano B, Bellucci AB, Vernace M, Wilkes BM, Mossey RT. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: A 20 year clinical experience. Am J Kidney Dis 1994; 24:622-629.
97. Scoble JE, Maher ER, Hamilton G, Dick R, Sweny P, Moorhead JF. Atherosclerotic renovascular disease causing renal impairment: A case for treatment. Clin Nephrol 1989; 31:119122.
98. Eardley KS, Lipkin GW. Atherosclerotic renal artery stenosis: Is it worth diagnosing? J Hum Hypertens 1999; 13:217-220.
99. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. Circulation 1998; 98:2866-2872.
100. Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001; 344:410-417.
101. Gerber BL, Ordoubadi FF, Wijns W, et al. Positron emission tomography using (18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: Optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of (18)F-fluoro-deoxyglucose positron emission tomography for the detection of myocardial viability. Eur Heart J 2001; 22:1691-1701.
102. Chabova V, Schirger A, Stanson AW, McKusick MA, Textor SC. Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin Proc 2000; 75:437-444.
103. Wollenweber J, Sheps SG, Davis GD. Clinical course of atherosclerotic renovascular disease. Am J Cardiol 1968; 21:60-71.
104. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
105. Dagenais GR, Yusuf S, Bourassa MG, et al. Effects of ramipril on coronary events in high-risk persons. Results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001; 104:522-526.
106. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contributions to alterations of vasomotor tome. J Clin Invest 1996; 97:1916-1923.
107. Dzau VJ. Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37:1047-1052.
108. Sheps SG, Osmundson PJ, Hunt JC, Schirger A, Fairbairn JF. Hypertension and renal artery stenosis: Serial observations on 54 patients treated medically. Clin Pharm Ther 1965; 6:700-709.
109. Isles C, Main J, O'Connell J, et al. Survival associated with renovascular disease in Glasgow and Newcastle: A collaborative study. Scot Med J 1990; 35:70-73.
110. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10:1606-1615.
111. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13(suppl 5):80-93.
112. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56:2214-2219.
113. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 134:629-636
114. Pfeffer MA, Braunwald E, Move LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327:669-677.
115. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular rejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
116. Jackson B, Franze L, Sumithran E, Johnston CI. Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat. J Lab Clin Med 1990; 115:21-27.
117. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
118. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
119. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157:2413-2446.
120. Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA 1985; 253:3263-3268.
121. Alderman MH, Lamport B. Labelling of hypertensives: A review of the data J. Clin Epidemiol 1990; 43:195-200.
122. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: Results from the Medical Outcomes Study. JAMA 1989; 262:907-913.
123. Oparil S, Calhoun DA. The calcium antagonists in the 1990s: An overview. Am J Hypertens 1991; 4(part 2):396S-405S.
124. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: Do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 1997; 278:1745-1748.
125. Okano GJ, Rascati KL, Wilson JP, Remund DD. A comparison of antihypertensive medication utilization before and after guideline changes using the Department of Defense Prescription Database. Ann Pharmacother 1999; 33:548-553.
126. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99:990-992.
127. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80:219-227.
128. Volpe M, Savoia C, Panina G, Cangianiello S. Therapeutic applications of angiotensin II receptor antagonists. Ann Endocrinol (Paris) 2000; 61:47-51.
129. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol Suppl 1996; 3:S125-S131.
130. Hunt JC, Sheps SG, Harrison EG, Strong CG, Bernatz PE. Renal and renovascular hypertension: A reasoned approach to diagnosis and management. Arch Intern Med 1974; 133:988-999.
131. Weibull H, Bergqvist D, Bergentz SE, Jonsson K, Hulthen L, Manhem P. Percutaneous transluminal renal angioplasty versus surgical reconstruction of atherosclerotic renal artery stenosis: A prospective randomized study. J Vasc Surg 1993; 18:841-850.
132. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis. Essai Multicentrique Medicaments vs. Angioplastie (EMMA) Study Group. Hypertension 1998; 31:823-829.
133. Webster J, Marshall F, Abdalla M, et al. Randomised comparison of percutaneous angioplasty vs. continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. J Hum Hypertens 1998; 12:329-335.
134. van Jaarsveld BC, Krijnen P, Pieterman H, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med 2000; 342:1007-1014.
135. Leertouwer TC, Gussenhoven EJ, Bosch JL, et al. Stent placement for renal arterial stenosis: Where do we stand? A meta-analysis. Radiology 2000; 216:78-85.
136. Hennequin LM, Joffre FG, Rousseau HP, et al. Renal artery stent placement: Long-term results with the Wallstent endoprosthesis. Radiology 1994; 191:713-719.
137. Blum U, Krumme B, Flugel P, et al. Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. N Engl J Med 1997; 336:459-465.
138. Baumgartner I, von Aesch K, Do DD, Triller J, Birrer M, Mahler F. Stent placement in ostial and nonostial atherosclerotic renal arterial stenoses: A prospective follow-up study. Radiology 2000; 216:498-505.
139. Kaatee R, Beek FJ, Verschuyl EJ, et al. Atherosclerotic renal artery stenosis: Ostial or truncal? Radiology 1996; 199: 637-640.